{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T15:12:23Z","timestamp":1785337943799,"version":"3.55.0"},"reference-count":19,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7,29]]},"DOI":"10.7759\/cureus.113596","type":"journal-article","created":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:45:41Z","timestamp":1785336341000},"source":"Crossref","is-referenced-by-count":0,"title":["Urgent Chemotherapy for Aggressive Metastatic Neuroendocrine Cancer With Impending Hepatic Failure: A Case Report"],"prefix":"10.7759","author":[{"given":"Gabriel B","family":"Rashba","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucas","family":"Kaplan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Bolos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Armine","family":"Baltayan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Simon","family":"Backer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1097\/MPA.0b013e3181ebb56f","article-title":"The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas","volume":"39","author":"Strosberg JR","year":"2010","unstructured":"Strosberg JR, Coppola D, Klimstra DS, Phan AT, Kulke MH, Wiseman GA, Kvols LK. The NANETS consensus guidelines for the diagnosis and management of poorly differentiated (high-grade) extrapulmonary neuroendocrine carcinomas. Pancreas. 2010, 39:799-800. 10.1097\/MPA.0b013e3181ebb56f","journal-title":"Pancreas"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1210\/endrev\/bnad006","article-title":"Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?","volume":"44","author":"Garcia-Carbonero R","year":"2023","unstructured":"Garcia-Carbonero R, Anton-Pascual B, Modrego A, et al.. Advances in the treatment of gastroenteropancreatic neuroendocrine carcinomas: are we moving forward?. Endocr Rev. 2023, 44:724-36. 10.1210\/endrev\/bnad006","journal-title":"Endocr Rev"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1530\/ERC-19-0483","article-title":"Extrapulmonary poorly differentiated NECs, including molecular and immune aspects","volume":"27","author":"McNamara MG","year":"2020","unstructured":"McNamara MG, Scoazec JY, Walter T. Extrapulmonary poorly differentiated NECs, including molecular and immune aspects. Endocr Relat Cancer. 2020, 27:R219-38. 10.1530\/ERC-19-0483","journal-title":"Endocr Relat Cancer"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.31124","article-title":"Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases","volume":"124","author":"Dasari A","year":"2018","unstructured":"Dasari A, Mehta K, Byers LA, Sorbye H, Yao JC. Comparative study of lung and extrapulmonary poorly differentiated neuroendocrine carcinomas: a SEER database analysis of 162,983 cases. Cancer. 2018, 124:807-15. 10.1002\/cncr.31124","journal-title":"Cancer"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1007\/s00117-024-01295-z","article-title":"Current WHO classification (2022) of neuroendocrine neoplasms [Article in German]","volume":"64","author":"Buchstab O","year":"2024","unstructured":"Buchstab O, Kn\u00f6sel T. Current WHO classification (2022) of neuroendocrine neoplasms [Article in German]. Radiologie (Heidelb). 2024, 64:531-5. 10.1007\/s00117-024-01295-z","journal-title":"Radiologie (Heidelb)"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15204951","article-title":"Selection of chemotherapy in advanced poorly differentiated extra-pulmonary neuroendocrine carcinoma","volume":"15","author":"Weaver JM","year":"2023","unstructured":"Weaver JM, Hubner RA, Valle JW, McNamara MG. Selection of chemotherapy in advanced poorly differentiated extra-pulmonary neuroendocrine carcinoma. Cancers (Basel). 2023, 15:4951. 10.3390\/cancers15204951","journal-title":"Cancers (Basel)"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mds276","article-title":"Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study","volume":"24","author":"Sorbye H","year":"2013","unstructured":"Sorbye H, Welin S, Langer SW, et al.. Predictive and prognostic factors for treatment and survival in 305 patients with advanced gastrointestinal neuroendocrine carcinoma (WHO G3): the NORDIC NEC study. Ann Oncol. 2013, 24:152-60. 10.1093\/annonc\/mds276","journal-title":"Ann Oncol"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.15.4377","article-title":"One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States","volume":"26","author":"Yao JC","year":"2008","unstructured":"Yao JC, Hassan M, Phan A, et al.. One hundred years after \"carcinoid\": epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol. 2008, 26:3063-72. 10.1200\/JCO.2007.15.4377","journal-title":"J Clin Oncol"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0000000000000408","article-title":"The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms","volume":"39","author":"Basturk O","year":"2015","unstructured":"Basturk O, Yang Z, Tang LH, et al.. The high-grade (WHO G3) pancreatic neuroendocrine tumor category is morphologically and biologically heterogenous and includes both well differentiated and poorly differentiated neoplasms. Am J Surg Pathol. 2015, 39:683-90. 10.1097\/PAS.0000000000000408","journal-title":"Am J Surg Pathol"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159\/000443167","article-title":"ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site","volume":"103","author":"Pavel M","year":"2016","unstructured":"Pavel M, O'Toole D, Costa F, et al.. ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology. 2016, 103:172-85. 10.1159\/000443167","journal-title":"Neuroendocrinology"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2009.22.8510","article-title":"Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group","volume":"27","author":"Rinke A","year":"2009","unstructured":"Rinke A, M\u00fcller HH, Schade-Brittinger C, et al.. Placebo-controlled, double-blind, prospective, randomized study on the effect of octreotide LAR in the control of tumor growth in patients with metastatic neuroendocrine midgut tumors: a report from the PROMID study group. J Clin Oncol. 2009, 27:4656-63. 10.1200\/JCO.2009.22.8510","journal-title":"J Clin Oncol"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1009290","article-title":"Everolimus for advanced pancreatic neuroendocrine tumors","volume":"364","author":"Yao JC","year":"2011","unstructured":"Yao JC, Shah MH, Ito T, et al.. Everolimus for advanced pancreatic neuroendocrine tumors. N Engl J Med. 2011, 364:514-23. 10.1056\/NEJMoa1009290","journal-title":"N Engl J Med"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2403991","article-title":"Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors","volume":"392","author":"Chan JA","year":"2025","unstructured":"Chan JA, Geyer S, Zemla T, et al.. Phase 3 trial of cabozantinib to treat advanced neuroendocrine tumors. N Engl J Med. 2025, 392:653-65. 10.1056\/NEJMoa2403991","journal-title":"N Engl J Med"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1002\/1097-0142(19910715)68:2<227::aid-cncr2820680202>3.0.co;2-i","article-title":"Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms","volume":"68","author":"Moertel CG","year":"1991","unstructured":"Moertel CG, Kvols LK, O'Connell MJ, Rubin J. Treatment of neuroendocrine carcinomas with combined etoposide and cisplatin. Evidence of major therapeutic activity in the anaplastic variants of these neoplasms. Cancer. 1991, 68:227-32. 10.1002\/1097-0142(19910715)68:2&lt;227::aid-cncr2820680202&gt;3.0.co;2-i","journal-title":"Cancer"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1038\/bjc.2016.229","article-title":"Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study","volume":"115","author":"Vijayvergia N","year":"2016","unstructured":"Vijayvergia N, Boland PM, Handorf E, et al.. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study. Br J Cancer. 2016, 115:564-70. 10.1038\/bjc.2016.229","journal-title":"Br J Cancer"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-15-1192","article-title":"BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy","volume":"6","author":"Klempner SJ","year":"2016","unstructured":"Klempner SJ, Gershenhorn B, Tran P, et al.. BRAFV600E mutations in high-grade colorectal neuroendocrine tumors may predict responsiveness to BRAF-MEK combination therapy. Cancer Discov. 2016, 6:594-600. 10.1158\/2159-8290.CD-15-1192","journal-title":"Cancer Discov"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1016\/j.esmoop.2021.100364","article-title":"Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms","volume":"7","author":"Al-Toubah T","year":"2022","unstructured":"Al-Toubah T, Halfdanarson T, Gile J, Morse B, Sommerer K, Strosberg J. Efficacy of ipilimumab and nivolumab in patients with high-grade neuroendocrine neoplasms. ESMO Open. 2022, 7:100364. 10.1016\/j.esmoop.2021.100364","journal-title":"ESMO Open"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1111\/jne.13443","article-title":"PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC)","volume":"37","author":"Sorbye H","year":"2025","unstructured":"Sorbye H, Kong G, Grozinsky-Glasberg S, Strosberg J. PRRT in high-grade digestive neuroendocrine neoplasms (NET G3 and NEC). J Neuroendocrinol. 2025, 37:e13443. 10.1111\/jne.13443","journal-title":"J Neuroendocrinol"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-019-0745-2","article-title":"DLL3: an emerging target in small cell lung cancer","volume":"12","author":"Owen DH","year":"2019","unstructured":"Owen DH, Giffin MJ, Bailis JM, Smit MD, Carbone DP, He K. DLL3: an emerging target in small cell lung cancer. J Hematol Oncol. 2019, 12:61. 10.1186\/s13045-019-0745-2","journal-title":"J Hematol Oncol"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/513602-urgent-chemotherapy-for-aggressive-metastatic-neuroendocrine-cancer-with-impending-hepatic-failure-a-case-report","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,29]],"date-time":"2026-07-29T14:45:41Z","timestamp":1785336341000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/513602-urgent-chemotherapy-for-aggressive-metastatic-neuroendocrine-cancer-with-impending-hepatic-failure-a-case-report"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7,29]]},"references-count":19,"URL":"https:\/\/doi.org\/10.7759\/cureus.113596","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2026,7,29]]}}}